Literature DB >> 9719479

Alpha-difluoromethylornithine (DFMO) as a potent arginase activity inhibitor in human colon carcinoma cells.

M Selamnia1, C Mayeur, V Robert, F Blachier.   

Abstract

Alpha-difluoromethylornithine (DFMO) is commonly used as a specific ornithine decarboxylase (ODC, EC4.1.1.17) irreversible inhibitor. ODC is the enzyme responsible for polyamine biosynthesis, which has been shown to be strictly necessary for cell proliferation. In HT-29 Glc-/+ cells, L-arginine is the major precursor of these molecules through the sequential actions of arginase, which leads to L-ornithine generation and ODC. L-ornithine, a substrate for ODC, retroinhibits arginase. Since DFMO is an ornithine analogue, we searched for a direct effect of this agent upon arginase. The flux of L-arginine through arginase in intact cells was inhibited by 51+/-11% by 10 mM of DFMO whereas 10 mM of L-valine, a known potent arginase inhibitor, inhibited this flux by 73+/-6%. DFMO equilibrated between extracellular and intercellular spaces and, when used at 10-mM concentration, was without effect on L-arginine net uptake. Measurement of arginase activity in HT-29 cell homogenates with increasing concentrations of DFMO and L-arginine led to an inhibition with a calculated Ki (inhibitory constant) equal to 3.9+/-1.0 mM. L-ornithine was less effective than DFMO in inhibiting arginase activity. Bovine liver arginase, used as another source of the enzyme, was also severely inhibited by DFMO. The inhibitory effect of DFMO upon arginase, one step upstream of the ODC reaction in the metabolic conversion of L-arginine to polyamines, is of potential physiological importance, since it could alter the production of ornithine and thus its metabolism in pathways other than the ODC pathway.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9719479     DOI: 10.1016/s0006-2952(97)00572-8

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  21 in total

1.  Arginine deprivation and immune suppression in a mouse model of Alzheimer's disease.

Authors:  Matthew J Kan; Jennifer E Lee; Joan G Wilson; Angela L Everhart; Candice M Brown; Andrew N Hoofnagle; Marilyn Jansen; Michael P Vitek; Michael D Gunn; Carol A Colton
Journal:  J Neurosci       Date:  2015-04-15       Impact factor: 6.167

Review 2.  Recent advances in arginine metabolism: roles and regulation of the arginases.

Authors:  Sidney M Morris
Journal:  Br J Pharmacol       Date:  2009-06-05       Impact factor: 8.739

3.  Binding of α,α-disubstituted amino acids to arginase suggests new avenues for inhibitor design.

Authors:  Monica Ilies; Luigi Di Costanzo; Daniel P Dowling; Katherine J Thorn; David W Christianson
Journal:  J Med Chem       Date:  2011-07-18       Impact factor: 7.446

Review 4.  Pharmacokinetics and Pharmacodynamics of Promising Arginase Inhibitors.

Authors:  Khaled S Abdelkawy; Kelsey Lack; Fawzy Elbarbry
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-06       Impact factor: 2.441

Review 5.  Metabolic mechanisms of tumor resistance to T cell effector function.

Authors:  Candace M Cham; Thomas F Gajewski
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

6.  Oxidized low-density lipoprotein inhibits nitric oxide-mediated coronary arteriolar dilation by up-regulating endothelial arginase I.

Authors:  Wei Wang; Travis W Hein; Cuihua Zhang; David C Zawieja; James C Liao; Lih Kuo
Journal:  Microcirculation       Date:  2011-01       Impact factor: 2.628

7.  Polyamine-blocking therapy reverses immunosuppression in the tumor microenvironment.

Authors:  Candace S Hayes; Allyson C Shicora; Martin P Keough; Adam E Snook; Mark R Burns; Susan K Gilmour
Journal:  Cancer Immunol Res       Date:  2013-10-07       Impact factor: 11.151

8.  Induction of arginase II by intestinal epithelium promotes the uptake of L-arginine from the lumen of Cryptosporidium parvum-infected porcine ileum.

Authors:  Jody L Gookin; Stephen H Stauffer; Maria R Stone
Journal:  J Pediatr Gastroenterol Nutr       Date:  2008-10       Impact factor: 2.839

Review 9.  Cancer pharmacoprevention: Targeting polyamine metabolism to manage risk factors for colon cancer.

Authors:  Eugene W Gerner; Elizabeth Bruckheimer; Alfred Cohen
Journal:  J Biol Chem       Date:  2018-10-24       Impact factor: 5.157

10.  The vascular effects of different arginase inhibitors in rat isolated aorta and mesenteric arteries.

Authors:  N N Huynh; E E Harris; J F P Chin-Dusting; K L Andrews
Journal:  Br J Pharmacol       Date:  2009-01       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.